Skip to main content
2023 AMDA Annual Conference Main banner
Conference Recordings

Education Program Details

Target Audience

The Society supports the entire interdisciplinary team and provides educational activities to be of value to the following post-acute and long-term care (PALTC) professionals:

  • Administrator
  • Attending Physician
  • Consultant Pharmacist
  • Dietician
  • Medical Director
  • Mental Health Professional
  • Nurse (DON, RN, LPN)
  • Practitioner (APN, PA)
  • Rehabilitation Professional
  • Respiratory Professional
  • Social Worker/Case Manager
  • Other Specialty Consultants

Overall Goal

The overall goal of this program is to enhance participants’ knowledge and competencies by providing the latest developments and tools available to improve the delivery of quality care in PALTC medicine.

Learning Objectives

Upon conclusion of participating in this educational activity, attendees should be able to:

  • Address the impact of racism and microaggression in the delivery of care in the PALTC environment.
  • Analyze available data to improve process and promote quality improvement in PALTC.
  • Discuss clinical advances and new research findings relevant to PALTC medicine.
  • Enhance skills and abilities to collaborate with and/or lead the PALTC interdisciplinary team.
  • Foster creativity and innovation in PALTC.
  • Gain new perspectives on relevant aspects of fiscal issues, health care policy, payment models, risk management and the Society’s policy priorities.
  • Implement Clinical Practice Guidelines (CPGs) in the PALTC setting.
  • Implement strategies for effective communication with patients, families and care teams.
  • Implement strategies to identify and address healthcare disparities in PALTC.
  • Incorporate and refine skills attitudes and knowledge to improve leadership effectiveness within a health care organization or facility.
  • Integrate knowledge and skills in assessment and management of ethical challenges and dilemmas in PALTC.
  • Integrate knowledge and skills gained to enhance the effectiveness and quality of medical direction in nursing facilities.
  • Utilize available data, tools, and emerging technologies to inform decisions about clinical care and/or medical direction.

Learner Assurance Statement and the Society Policy on Disclosure and Resolution of Conflict of Interest

It is the Society’s policy that all those in a position to directly control CME content, such as, planning committees, faculty, and authors, disclose any relationships with commercial entities upon nomination or invitation for participation. Disclosure documents are reviewed in advance for potential conflicts of interest. If conflicts are identified, they are resolved prior to confirmation of participation to ensure participation and/or presentation is non-biased/ promotional, evidence-based and scientifically sound. Only those participants who had no conflict of interest or who agreed to an identified resolution process prior to their participation are involved in this CME activity.


Disclosures of Relevant Financial Relationships

All relationships disclosed by those in control of content have been noted in conference materials. Financial relationships with Ineligible Companies* relevant to the content of the conference are as follows and have been mitigated:

  • Muhammad Salman Ashraf, MBBS: Merck & Co Inc: Contracted Research
  • H. Edward Davidson, PharmD, MPH: Genentech: Clinical Trial Investigator; Janssen Pharmaceuticals: Clinical Trial Investigator; Sanofi Aventis: Clinical Trial Investigator
  • Ghinwa Dumyati, MD: Pfizer: Contracted Research (Ended, December 31, 2021)
  • Julie Gammack, MD, CMD (Planner & Speaker): Stockholder: Amarin
  • Stefan Gravenstein, MD, MPH: Genentech: Advisory Board|Genentech: Contracted Research|GlaxoSmithKline: Advisory Board|GlaxoSmithKline: Honorarium|Icosavax: Advisory Board|Janssen: Advisory Board|Janssen: Speaker's Bureau|Longevoron: Data Safety Monitoring Board|Merck: SRC (Ended, January 1, 2020)|Moderna: Consultant|Novavax: Advisory Board|Pfizer: Advisory Board|Pfizer: Contracted Research|Pfizer: Speaker's Bureau|Sanofi: Advisory Board|Sanofi: Contracted Research|SciClone: Data Safety Monitoring Board|Seqirus: Contracted Research|Seqirus: Speaker's Bureau|Sequirus: Contracted Research|Sequirus: Honorarium|VaxArt: Advisory Board
  • Irene Hamrick, MD, CMD: Arkray: Consultant
  • Robin Jump, MD, PhD: Merck: Contracted Research|Pfizer: Advisory Board|Pfizer: Contracted Research|Pfizer: Honorarium
  • Meenakshi Patel, MD, FACP, MMM, CMD: Bayer: Speaker's Bureau|Eli Lilly: Advisory Board|Eli Lilly: Clinical Trial Investigator|Eli Lilly: Contracted Research|Eli Lilly: Speaker's Bureau|Janssen Pharmaceuticals: Clinical Trial Investigator|Janssen Pharmaceuticals: Contracted Research|Janssen Pharmaceuticals: Speaker's Bureau|Neurim: Contracted Research|Novo Nordisk: Contracted Research|TEVA: Speaker's Bureau|Urovant: Advisory Board|Urovant: Speaker's Bureau
  • Kenya Rivas Velasquez, MD, CMD, FAAFP (Planner & Speaker): OptumRx: Stockholder
  • Elie Saade, MD, MPH, FIDSA: Janssen Pharmaceuticals: Contracted Research (Ended, December 31, 2020)|Janssen Pharmaceuticals: Clinical trial steering committee|Janssen Pharmaceuticals: Speaker's Bureau|Pfizer: Clinical Trial Investigator|Pfizer: Contracted Research|Sanofi Pasteur: Contracted Research (Ended, March 31, 2022)
  • Todd Sobol, MD, FACP, CMD: CareBand: Advisory Board|CareBand: Stockholder/Ownership Interest (excluding diversified mutual funds)
  • Brandon Verdoorn, MD, CMD: Bristol Myers Squibb: Stockholders (excluding diversified mutual funds)

No one else in control of content has any relevant financial relationships with *"companies whose primary business is producing, marketing, selling, re-selling, or distributing healthcare products used by or on patients."

Back to Top